N-0385

N-O385 is an anti-viral drug developed to counter variants of concern (VOCs) of the novel coronavirus. This drug is found to stop SARS-CoV-2 virus from entering the human cells and damaging the lungs. It was also found to be effective against B.1.1.7 (UK variant) and B.1.351 (South African variant). The drug blocks the virus’s enzyme that is involved in cutting and priming the viral spike protein so that it attaches with the host cell’s membrane and release the virus’s genetic material.